ada.enesco, Author at European Medical Journal - Page 10 of 65

New Gene-Pollution Link Found in Asthma

A Taiwanese study identifies lncZPBP2-3 as a pollution-responsive gene variant that heightens asthma risk with long-term PM2.5 exposure.

Changes in Oral Microbiome Linked to Relapsing-Remitting Multiple Sclerosis

New study shows oral microbiome imbalance and reduced salivary hypotaurine may contribute to neuroinflammation in relapsing-remitting MS.

IDWeek 2025: Zoster Vaccine Linked to Lower Cardiovascular, Dementia Risk

Prior zoster vaccination reduces risks of cardiovascular events, dementia, and death after shingles infection, new IDWeek 2025 data show.

IDWeek 2025: C. diff Deaths Show Stark Demographic Gaps

A 25-year USA study finds C. diff deaths highest among White people, women, and city residents, though overall mortality has fallen since 2015.

Reducing Postoperative Urinary Retention in Surgery

Several risk factors increase the likelihood of postoperative urinary retention, including general or opioid-based anaesthesia and underlying benign prostatic hyperplasia.

ALS and MS Share Surprising Environmental Patterns

A geographical analysis shows ALS and MS follow nearly identical patterns, suggesting shared environmental influences behind both diseases.

Enhancing PPIE in Allergy Research and Practice

Enhancing PPIE in allergic disease research offers tangible benefits, from improving patient outcomes to ensuring studies align with real-world needs.

EACS 2025: Doxy-PEP Cuts Chlamydia and Syphilis Risk in Men Living With HIV

EACS 2025 study shows doxycycline prophylaxis reduced chlamydia and syphilis rates in Swiss men with HIV, with no effect against gonorrhoea.

EACS 2025: Over Half of HIV Diagnoses in Migrants Occur Years Post-Migration

EACS 2025 data show over half of HIV diagnoses among migrants in Switzerland occur post-migration, highlighting need for targeted testing and prevention.

EACS 2025: Low Risk of HBV Reactivation After Tenofovir Withdrawal in People With HIV

EACS 2025 study shows minimal HBV reactivation after stopping tenofovir in people with HIV, supporting safe use of tenofovir-sparing ART.